Overview

Sevelamer and Secondary Hyperparathyroidism in Chronic Kidney Disease

Status:
Completed
Trial end date:
2013-04-01
Target enrollment:
Participant gender:
Summary
The hypothesis underlying this study is that phosphate interferes with PTH-mediated calcium reabsorption in the distal nephron and thereby necessitates supranormal [PTH]to maintain normocalcemia in chronic kidney disease. This study will examine the hypothesis with measures of phosphate homeostasis and calcium reabsorption. A double-blind trial of the intestinal phosphate binder sevelamer carbonate will be employed to examine whether reductions in phosphate influx alter distal nephron phosphate concentration and the [PTH] required for calcium reabsorption in the expected manner.
Phase:
Phase 3
Details
Lead Sponsor:
Kenneth R. Phelps, M.D.
Collaborator:
Genzyme, a Sanofi Company
Treatments:
Sevelamer